In conversation with... Bernardo Goulart

from Listen to The Lancet Oncology · host The Lancet

Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer.

Episode metadata supplied by the publisher feed · Published Apr 9, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

In conversation with... Bernardo Goulart

0:00 11:22

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Oncology?

This episode is 11 minutes long.

When was this Listen to The Lancet Oncology episode published?

This episode was published on April 9, 2024.

Can I download this Listen to The Lancet Oncology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!